Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $4.94M rose 17.1% year over year, behind the +170.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -40.6% a year.

Context

  • Accounts payables amounted to 7.1% of revenue in FY2025, down 17.4 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +170.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.94M+427.8% QoQ
Last fiscal yearDec 2025
$2.79M+119.7% YoY
LTMMar 2026
$3.51M+170.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.1%——
1 year+119.7%——
3-year CAGR-40.6%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.79M USD
Year-over-year change
+119.7%

Accounts Payables vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +170.1% is the highest of 10, against a peer median of -70.4%.
  • Accounts payables amounts to 10.2% of revenue for SGMO, versus a peer median of 4.5%.
SGMO Competitors
Accounts Payables for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.58M USD+55.9%—425.1%
IVVDInvivyd, Inc.LTM Mar 2026$6.72M USD-188.7%—12.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$3.51M USD+170.1%-40.6%10.2%
CDXSCodexis, Inc.LTM Mar 2026$3.04M USD-297.9%—3.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$662K USD-192.7%—20.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 504.13K CHF-32.5%——
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$337K USD-70.4%+107.3%17.3%
OABIOmniAb, Inc.LTM Mar 2026$215K USD+111.0%—0.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$133K USD-95.3%—4.5%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K USD+109.7%-48.0%0.3%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
Peer median (excluding SGMO) —-70.4%+29.6%4.5%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.